4.6 Review

Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Urology & Nephrology

The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients

Megan Borkum et al.

Summary: Current kidney and heart outcome trials have excluded patients with a glomerular filtration rate below 25 mL/min/1.73 m2. However, dialysis patients, who are at the highest risk of cardiovascular disease, would benefit greatly from effective cardioprotective therapies. Emerging evidence suggests that SGLT2 inhibitors may be well-tolerated and effective in preventing cardiovascular and mortality outcomes in patients with severe chronic kidney disease, including those undergoing dialysis.

PERITONEAL DIALYSIS INTERNATIONAL (2023)

Article Hematology

Dialysis Outcomes in a Middle-Income Country: An Updated Comparison of Patient Mortality between Hemodialysis and Peritoneal Dialysis

Rafael M. Sanabria et al.

Summary: The study compared mortality rates between patients on HD and PD, finding no significant difference in cumulative mortality after at least 5 years of follow-up.

BLOOD PURIFICATION (2022)

Article Endocrinology & Metabolism

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

Janaka Karalliedde et al.

Summary: A significant percentage of people with diabetes develop chronic kidney disease and diabetes is a leading cause of end-stage kidney disease. Hyperglycemia is a modifiable risk factor for cardiovascular complications and progression of DKD. Recent clinical trials have shown the benefits of SGLT-2 inhibitors in improving clinical outcomes for DKD patients.

DIABETIC MEDICINE (2022)

Article Urology & Nephrology

Propensity-matched comparison of mortality between peritoneal dialysis and hemodialysis in patients with type 2 diabetes

Hui Liu et al.

Summary: This study compared mortality rates between peritoneal dialysis (PD) and hemodialysis (HD) in end-stage renal disease (ESRD) patients with type 2 diabetes, finding no significant difference in patient survival rates between the two modalities. Different risk factors associated with mortality were identified for patients receiving PD versus HD treatment.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)

Article Urology & Nephrology

24-h Glycaemic profiles in peritoneal dialysis patients and non-dialysis controls with advanced kidney disease

Jennifer Williams et al.

Summary: This study compared 24-hour glycemic profiles of PD patients without diabetes with CKD-5 controls using continuous glucose monitoring (CGM). The results showed systematically different glycemic patterns in APD and CAPD patients, including higher nocturnal glucose in APD and absence of physiological nocturnal glucose dipping in APD. Comprehensive CGM data highlighted subtleties not appreciated by traditional metabolic biomarkers, suggesting implications for future research on the metabolic impact of PD.

PERITONEAL DIALYSIS INTERNATIONAL (2022)

Article Urology & Nephrology

Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations

Paul N. Bennett et al.

Summary: The importance of physical activity and function for patients receiving peritoneal dialysis is highlighted in this text, with clinical practice points developed by the Global Renal Exercise Network and the International Society for Peritoneal Dialysis. Sparse quality evidence led to the reliance on expert consensus for the development of these practice points.

PERITONEAL DIALYSIS INTERNATIONAL (2022)

Review Pharmacology & Pharmacy

Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis

Emily Blaine et al.

Summary: Chronically uncontrolled hyperglycemia is a common factor in end stage kidney disease (ESKD) that requires dialysis. However, there is a lack of clear clinical recommendations for adjusting insulin dosing during the transition to hemodialysis (HD) or peritoneal dialysis (PD).

PHARMACOTHERAPY (2022)

Review Endocrinology & Metabolism

Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease

James Ling et al.

Summary: Diabetes is the leading cause of chronic kidney disease (CKD) in developed countries, with optimal glycemic control being important in reducing the risk of CKD progression and related death. However, assessing glycemic control in advanced CKD and dialysis patients can be challenging. Continuous glucose monitoring (CGM) systems provide an alternative and more reliable method of glycemic assessment, although further studies are needed to confirm their accuracy and cost-effectiveness in this population.

FRONTIERS IN ENDOCRINOLOGY (2022)

Article Urology & Nephrology

Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring

Tobias Bomholt et al.

Summary: Shortened erythrocyte life span and erythropoietin-stimulating agents may affect hemoglobin A(1c) levels in patients receiving peritoneal dialysis. Comparison of HbA(1c) with interstitial glucose measured by continuous glucose monitoring found that HbA(1c) underestimates mean plasma glucose levels in PD patients. Fructosamine may more accurately reflect glycemic status in this population.

NEPHRON (2022)

Article Urology & Nephrology

Associations between diabetes and sex with peritoneal dialysis technique and patient survival: Results from the Australia and New Zealand Dialysis and Transplant Registry cohort study

Jenny H. C. Chen et al.

Summary: This study found that peritoneal dialysis patients with diabetic nephropathy had increased risk of PD technique failure and mortality, with these risks being greater in women.

PERITONEAL DIALYSIS INTERNATIONAL (2021)

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial

Stefan D. Anker et al.

Summary: In patients with chronic heart failure with reduced ejection fraction, empagliflozin significantly improved cardiovascular and renal outcomes, regardless of baseline diabetes status, and across the continuum of HbA1c.

CIRCULATION (2021)

Article Urology & Nephrology

SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis

Giedre Martus et al.

Summary: In this study, SGLT2 inhibition with Empagliflozin was found to increase urinary glucose excretion and lower plasma glucose levels during peritoneal dialysis in rats, without affecting sodium or water transport across the peritoneal barrier.

PERITONEAL DIALYSIS INTERNATIONAL (2021)

Article Biochemistry & Molecular Biology

Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial

Charlotte K. Boughton et al.

Summary: In this study, fully closed-loop insulin therapy was found to improve glucose control and reduce hypoglycemia compared to standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial demonstrated increased time in target glucose range and decreased risk of hypoglycemia in patients with type 2 diabetes who require dialysis.

NATURE MEDICINE (2021)

Review Transplantation

New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review

Cheng Xue et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)

Editorial Material Urology & Nephrology

FOREWORD

Alison Steiber et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Urology & Nephrology

An Exercise Program for Peritoneal Dialysis Patients in the United States: A Feasibility study

Paul N. Bennett et al.

KIDNEY MEDICINE (2020)

Article Urology & Nephrology

Hypoglycemia in People with Type 2 Diabetes and CKD

Iram Ahmad et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

Article Medicine, Research & Experimental

SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2

Ying Zhou et al.

BIOMEDICINE & PHARMACOTHERAPY (2019)

Review Medical Laboratory Technology

The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement

Randie R. Little et al.

CLINICAL CHEMISTRY (2019)

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Endocrinology & Metabolism

Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes

P. A. Dyson et al.

DIABETIC MEDICINE (2018)

Article Medicine, General & Internal

Assessment of Global Kidney Health Care Status

Aminu K. Bello et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Endocrinology & Metabolism

SGLT2 Inhibitors and the Diabetic Kidney

Paola Fioretto et al.

DIABETES CARE (2016)

Editorial Material Urology & Nephrology

NEW-ONSET DIABETES IN PERITONEAL DIALYSIS PATIENTS - WHICH PREDICTORS REALLY MATTER?

Matthew B. Rivara et al.

PERITONEAL DIALYSIS INTERNATIONAL (2016)

Article Endocrinology & Metabolism

Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: The DIALYDIAB pilot study

Michael Joubert et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2015)

Article Endocrinology & Metabolism

Impact of carbamylation on three different methods, HPLC, capillary electrophoresis and TINIA of measuring HbA1c levels in patients with kidney disease

Ramona C. Dolscheid-Pommerich et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2015)

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Urology & Nephrology

Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated With Hemodialysis: A Meta-analysis

Christopher J. Hill et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2014)

Review Urology & Nephrology

Practical Considerations When Prescribing Icodextrin: A Narrative Review

Samuel A. Silver et al.

AMERICAN JOURNAL OF NEPHROLOGY (2014)

Article Urology & Nephrology

Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry

Gabriel Mircescu et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2014)

Article Endocrinology & Metabolism

Epidemiology and Mortality of New-Onset Diabetes After Dialysis Taiwan national cohort study

Kai-Jen Tien et al.

DIABETES CARE (2013)

Article Urology & Nephrology

Randomized, Controlled Trial of Glucose-Sparing Peritoneal Dialysis in Diabetic Patients

Philip K. T. Li et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)

Article Medicine, General & Internal

Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease

Rajnish Mehrotra et al.

ARCHIVES OF INTERNAL MEDICINE (2011)

Article Urology & Nephrology

Glycated Albumin and Risk of Death and Hospitalizations in Diabetic Dialysis Patients

Barry I. Freedman et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)

Article Urology & Nephrology

Glycemic Control and Survival in Peritoneal Dialysis Patients with Diabetes Mellitus

Uyen Duong et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)

Article Medicine, General & Internal

Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study

Craig J. Currie et al.

LANCET (2010)

Article Urology & Nephrology

Relationship between Dialysis Modality and Mortality

Stephen P. McDonald et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)

Article Endocrinology & Metabolism

Translating the A1C assay into estimated average glucose values

David M. Nathan et al.

DIABETES CARE (2008)

Review Endocrinology & Metabolism

Insulin therapy in renal disease

Pedro Iglesias et al.

DIABETES OBESITY & METABOLISM (2008)

Article Transplantation

Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis

Cheuk-Chun Szeto et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)

Article Anesthesiology

Significant hypoglycemia secondary to icodextrin peritoneal dialysate in a diabetic patient

Henry R. Kroll et al.

ANESTHESIA AND ANALGESIA (2007)

Article Endocrinology & Metabolism

A1C and survival in maintenance hemodialysis patients

Kamyar Kalantar-Zadeh et al.

DIABETES CARE (2007)

Article Urology & Nephrology

New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis

Cheuk-Chun Szeto et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2007)

Article Transplantation

The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids

Nicholas M. Selby et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)

Article Urology & Nephrology

Mortality studies comparing peritoneal dialysis and hemodialysis: What do they tell us?

E. F. Vonesh et al.

KIDNEY INTERNATIONAL (2006)